Although such studies only tested limited sample size without direct comparison between IBC tumors and non-IBC tumors [16, 18], ALK has been suggested as a potential druggable target in IBC patients, and its clinical implication and prognostic significance needs to be elucidated. The gene discussed is ALK; the disease is inflammatory breast carcinoma.